Foresite Capital Management V LLC Buys Shares of 67,356 Natera, Inc. $NTRA

Foresite Capital Management V LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 67,356 shares of the medical research company’s stock, valued at approximately $15,431,000. Natera makes up approximately 9.4% of Foresite Capital Management V LLC’s portfolio, making the stock its 4th biggest position.

Other hedge funds have also made changes to their positions in the company. Horizon Investments LLC lifted its holdings in Natera by 22.0% in the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after purchasing an additional 44 shares during the last quarter. Sound Income Strategies LLC grew its holdings in Natera by 20.0% during the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after purchasing an additional 45 shares during the last quarter. Savvy Advisors Inc. raised its position in shares of Natera by 3.1% in the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after purchasing an additional 46 shares during the period. Siemens Fonds Invest GmbH lifted its stake in shares of Natera by 3.1% in the third quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after buying an additional 54 shares during the last quarter. Finally, Alamea Verwaltungs GmbH lifted its stake in shares of Natera by 2.9% in the fourth quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock worth $515,000 after buying an additional 62 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Robert W. Baird set a $265.00 price objective on shares of Natera in a report on Friday, May 8th. Wolfe Research started coverage on shares of Natera in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 target price for the company. William Blair initiated coverage on shares of Natera in a report on Tuesday, April 14th. They set an “outperform” rating for the company. Piper Sandler reaffirmed an “overweight” rating and issued a $249.00 price target on shares of Natera in a research report on Tuesday, May 12th. Finally, JPMorgan Chase & Co. lifted their price objective on Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $256.53.

Insiders Place Their Bets

In other Natera news, insider John Fesko sold 1,438 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $202.84, for a total value of $291,683.92. Following the completion of the sale, the insider owned 185,782 shares in the company, valued at approximately $37,684,020.88. This trade represents a 0.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $218.43, for a total value of $655,290.00. Following the sale, the insider directly owned 137,643 shares in the company, valued at $30,065,360.49. The trade was a 2.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 159,378 shares of company stock valued at $34,640,860 in the last quarter. 5.05% of the stock is currently owned by insiders.

Natera Price Performance

NASDAQ NTRA opened at $216.97 on Tuesday. The company’s fifty day moving average is $206.67 and its two-hundred day moving average is $215.69. Natera, Inc. has a 52-week low of $131.81 and a 52-week high of $256.36. The firm has a market capitalization of $31.07 billion, a price-to-earnings ratio of -133.11 and a beta of 1.56.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.